The Ras/Raf/MAPK pathway

Journal of Thoracic Oncology

Volumn 1, Issue 1, 2006, Pages 7-9

  Molina, Julian R ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ARRY 142886; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GERANYLGERANYLTRANSFERASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SORAFENIB; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANGIOGENESIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CATALYSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CYTOLOGY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; CELL CYCLE; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; REVIEW;

CELL CYCLE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; RAF KINASES; SIGNAL TRANSDUCTION;

EID: 33748367532     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200601000-00004     Document Type: Short Survey

References (25)

1. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 2003;15:pp. 158-163.
2. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P. The epidermal growth factor. Cell Biol. Int. 1995;19:pp. 413-430.
3. Cary LA, Han DC, Guan JL. Integrin-mediated signal transduction pathways. Histol. Histopathol. 1999;14:pp. 1001-1009.
4. Kranenburgm O, Gebbink MF, Voest EE. Stimulation of angiogenesis by Ras proteins. Biochim. Biophys. Acta 2004;1654:pp. 23-37.
5. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire AP, Meert AP, Noel S, Lafitte J.J J.P. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer. 2006;92:pp. 131-139.
6. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, Crissman JD, Sarkar FH. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol. 1997;21:pp. 127-143.
7. Galiana C, Lozano JC, Bancel B, Nakazawa H, Yamasaki H. High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol. Carcinog. 1995;14:pp. 286-293.
8. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res. Treat. 2000;62:pp. 51-62.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
10. C Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RG, Wang TL, Shih IM. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin. Cancer Res. 2004;10:pp. 6432-6436.
11. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer. Inst. 2001;93:pp. 1062-1074.
12. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
13. Ghobrial IM, Adjei AA. Inhibitors of the ras oncogene as therapeutic targets. Hematol. Oncol. Clin. N. Am. 2002;16:pp. 1065-1088.
14. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell. Signal. 2001;13:pp. 777-785.
15. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res. 2001;56:pp. 127-155.
16. Cantrell DA. GTPases and T cell activation. Immunol. Rev. 2003;192:pp. 122-130.
17. Schlessinger J. Cell Signaling by receptor tyrosine kinases. Cell. 2000; 103:pp. 211-225.
18. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14:pp. 3136-3145.
19. Schlesinger TK, Fanger GR, Yujiri T, Johnson GL. The TAO of MEKK. Front. Biosci. 1998;3:pp. D1181-D1186.
20. Karandikar M, Xu S, Cobb MH. MEKK1 binds raf-1 and the ERK2 cascade components. J. Biol. Chem. 2000;275:pp. 40120-40127.
21. Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, Lamb ML, Kohman LJ, Poiesz BJ. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999;17:668-75.
22. Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res. 1996;2:411-8.
23. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst. 1999;91:2032-8.
24. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis. 1999;20:1507-10.
25. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2006;23:5900-9.